Bone Metastases and Use of Bone Protective Agents for Metastatic Clear Cell Renal Cell Carcinoma: A Contemporary National Real-World Analysis
Braden Millan(National Cancer Institute), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Bimal Bhindi, Georg A. Bjarnason(Sunnybrook Health Science Centre), Lori Wood(Dalhousie University), Vincent Castonguay(Centre hospitalier universitaire de Québec), Daniel Yick Chin Heng(University of Calgary), Sunita Ghosh(University of Alberta), Dominick Bosse(University of Ottawa), Eric Winquist(Western University), Naveen S. Basappa(University of Alberta), Rodney H. Breau(Ottawa Hospital), Antonio Finelli(University of Toronto), Rahul K. Bansal(St. Joseph’s Healthcare Hamilton), Jeffrey Graham(CancerCare Manitoba), Christian K. Kollmannsberger(BC Cancer Agency), Frédéric Pouliot(Université Laval)
Cited by 0
Related Papers
Exosomes Induce Fibroblast Differentiation into Cancer-Associated Fibroblasts through TGFβ Signaling
|Molecular Cancer Research|2018|322
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
|Journal for ImmunoTherapy of Cancer|2018|267
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
|Journal of Clinical Oncology|2014|233
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
|Nature Communications|2019|225